Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrd.2016.279 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of High-Incidence Populations in the United States for Anti-Epstein-Barr Virus Serologic Screening for Nasopharyngeal Carcinoma.
Cancer Epidemiol Biomarkers Prev
December 2024
Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Article Synopsis
- EBV-related nasopharyngeal carcinoma (NPC) significantly affects Asian Americans and Native Hawaiians/other Pacific Islanders in the U.S. who lack screening access, and early detection has proven effective in Asian trials.
- Analysis of NPC incidence data highlighted that 10.7% of the U.S. population accounts for 42.7% of NPC cases, with anti-BNLF2b screening being the most effective method, potentially reducing mortality significantly.
- The recommended target group for NPC screening in the U.S. consists of certain ethnic men and women aged 35 to 65, indicating that a one-time screening approach could be both effective and economically feasible.
Differences in tumor-associated T-cell receptor repertoires between early-onset and average-onset colorectal cancer.
J Natl Cancer Inst
October 2024
Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
The incidence of colorectal cancer (CRC) among individuals younger than age 50 (early-onset CRC [EOCRC]) has substantially increased, and yet the etiology and molecular mechanisms underlying this alarming rise remain unclear. We compared tumor-associated T-cell repertoires between EOCRC and average-onset CRC (AOCRC) to uncover potentially unique immune microenvironment-related features by age of onset. Our discovery cohort included 242 patients who underwent surgical resection at Cleveland Clinic from 2000 to 2020.
View Article and Find Full Text PDFEfficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol
August 2024
Center for Gynecologic Cancer, National Cancer Center, Goyang, Republic of Korea; Cancer Control and Policy, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea; Rare&Paediatric Cancer Branch and Immuno-oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea. Electronic address:
Background: The combination of immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy has emerged as a highly promising primary option for advanced or recurrent endometrial cancer (EC). The study aimed to evaluate treatment efficacy of ICIs with cytotoxic chemotherapy in EC.
Methods: We conducted a comprehensive review of randomized controlled trials up to November 11, 2023, focusing on immunotherapy combined with chemotherapy versus chemotherapy alone for EC.
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020.
J Natl Cancer Inst
July 2024
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Background: We described participant demographics for National Cancer Institute (NCI) clinical trials at the clinical center (NCI-CC participants) of the National Institutes of Health to identify enrollment disparities.
Methods: We analyzed NCI-CC data from 2005 to 2020, calculated enrollment fractions, compared with the US cancer population represented by the Surveillance, Epidemiology, and End Results cancer incidence data (2018) and the Cancer in North America database (2018), and compared further with clinical trial disparities data from the NCI Community Oncology Research Program and National Clinical Trials Network (2005-2019), and from ClinicalTrials.gov (2003-2016).
A novel class of inhibitors that disrupts the stability of integrin heterodimers identified by CRISPR-tiling-instructed genetic screens.
Nat Struct Mol Biol
March 2024
Department of Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Article Synopsis
- The researchers used CRISPR screens to identify critical integrin proteins, ITGAV and ITGB5, that are vital for cancer cell growth in various cancer models.* -
- They developed a new drug discovery method called CRISPR-TICA, which combines CRISPR gene tiling and computer-aided design to find potential drug candidates like Cpd_AV2, targeting a specific pocket on ITGAV.* -
- Treatment with Cpd_AV2 leads to the breakdown of the integrin αVβ5 complex and triggers cell death, showcasing a novel therapeutic strategy focused on disrupting integrin signaling.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!